OrbusNeich Release: COMBO Dual Therapy Stent™ Clinical Results to be Featured at EuroPCR 2013
5/13/2013 7:43:55 AM
More...
|
OrbusNeich Enforces Injunction Against Boston Scientific Corporation (BSX) in Germany
5/7/2013 10:01:51 AM
More...
|
Data Published in JACC: Cardiovascular Interventions Show That OrbusNeich's COMBO Dual Therapy Stent™ Reaches Primary Study Endpoint and is Effective in Controlling Neointimal Proliferation
4/17/2013 9:10:29 AM
More...
|
OrbusNeich File Patent Infringement Lawsuit Against Boston Scientific Corporation (BSX) in Ireland
3/8/2013 9:35:36 AM
More...
|
OrbusNeich Files Patent Infringement Actions Against Boston Scientific Corporation (BSX) in Germany and the Netherlands
2/20/2013 10:06:19 AM
More...
|
OrbusNeich Announces Favorable Ruling From the European Patent Office
2/12/2013 9:01:44 AM
More...
|
OrbusNeich's COMBO Dual Therapy Stent™ to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012
10/16/2012 10:53:11 AM
More...
|
OrbusNeich's Genous™ Stent Is Safe and Effective in Patients Who Discontinue Dual Antiplatelet Therapy (DAPT) Within 15 Days of Stent Placement
6/22/2012 10:20:37 AM
More...
|
Early Coronary Artery Healing Advantage of OrbusNeich's Combo Dual Therapy Stent(TM) Compared to the TAXUS(R) Stent Shown in Two Clinical Trial Subgroup Analyses
5/18/2012 10:01:32 AM
More...
|
OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
5/15/2012 12:49:51 PM
More...
|
|